LYVE1 anticorps

N° du produit ABIN289493

Il existe 8+ publications pour ce produit. L’anticorps anti-LYVE1 Polyclonal Lapin est utilisé pour la détection de LYVE1 dans des échantillons de Souris. Il a été validé pour WB, ELISA et FACS.

Aperçu rapide pour LYVE1 anticorps (ABIN289493)

Antigène: LYVE1 (Lymphatic Vessel Endothelial Hyaluronan Receptor 1 (LYVE1))

Reactivité: Souris

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp LYVE1 est non-conjugé

Application: Western Blotting (WB), ELISA, Flow Cytometry (FACS)

Détail du produit anti-LYVE1 anticorps

Purification: Protein A affinity chromatography

Immunogène: LYVE1 antibody was raised in rabbit using recombinant mouse soluble Lyve-1 as the immunogen.

Isotype: IgG

Information d'application

Indications d'application: ELISA: 1-15 µg/mL, FC: 3-10 µg/mL, WB:2-5 µg/mL
Optimal conditions should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Format: Lyophilized

Concentration: Lot specific

Buffer: Supplied in lyophilized formin PBS buffer

Conseil sur la manipulation: Avoid repeated freeze/thaw cycles.
Dilute only prior to immediate use.

Stock: 4 °C/-20 °C

Stockage commentaire: Store at -20 °C until reconstitution. Following reconstitution product may be stored at 4 °C in the short term. For long term storage aliquot and freeze at -20 °C.

Références pour anticorps anti-LYVE1 (ABIN289493)

Piao, Xiong, Li, Saxena, Smith, Hippen, Paluskievicz, Willsonshirkey, Blazar, Abdi, Bromberg: "Regulatory T Cells Condition Lymphatic Endothelia for Enhanced Transendothelial Migration." dans: Cell reports, Vol. 30, Issue 4, pp. 1052-1062.e5, (2020) (PubMed).

Bourland, Fradette, Auger: "Tissue-engineered 3D melanoma model with blood and lymphatic capillaries for drug development." dans: Scientific reports, Vol. 8, Issue 1, pp. 13191, (2019) (PubMed).

Piao, Xiong, Famulski, Brinkman, Li, Toney, Wagner, Saxena, Simon, Bromberg: "Regulation of T cell afferent lymphatic migration by targeting LTβR-mediated non-classical NFκB signaling." dans: Nature communications, Vol. 9, Issue 1, pp. 3020, (2018) (PubMed).

Le, Nowell, Kim-Fuchs, Botteri, Hiller, Ismail, Pimentel, Chai, Karnezis, Rotmensz, Renne, Gandini, Pouton, Ferrari, Möller, Stacker, Sloan: "Chronic stress in mice remodels lymph vasculature to promote tumour cell dissemination." dans: Nature communications, Vol. 7, pp. 10634, (2016) (PubMed).

Brinkman, Iwami, Hritzo, Xiong, Ahmad, Simon, Hippen, Blazar, Bromberg: "Treg engage lymphotoxin beta receptor for afferent lymphatic transendothelial migration." dans: Nature communications, Vol. 7, pp. 12021, (2016) (PubMed).

Stefanini, Paul, Robledo, Chan, Getz, Campbell, Kechele, Casari, Piatt, Caron, Mackman, Weyrich, Parrott, Boulaftali, Adams, Peters, Bergmeier: "RASA3 is a critical inhibitor of RAP1-dependent platelet activation." dans: The Journal of clinical investigation, Vol. 125, Issue 4, pp. 1419-32, (2015) (PubMed).

Owens, Pickup, Novitskiy, Giltnane, Gorska, Hopkins, Hong, Moses: "Inhibition of BMP signaling suppresses metastasis in mammary cancer." dans: Oncogene, Vol. 34, Issue 19, pp. 2437-49, (2015) (PubMed).

Yücel, Johnston, Ly, Patel, Drake, Gümüş, Fraenkl, Moore, Tobbia, Armstrong, Horvath, Gupta: "Identification of lymphatics in the ciliary body of the human eye: a novel "uveolymphatic" outflow pathway." dans: Experimental eye research, Vol. 89, Issue 5, pp. 810-9, (2009) (PubMed).

Détails sur LYVE1

Antigène: LYVE1 (Lymphatic Vessel Endothelial Hyaluronan Receptor 1 (LYVE1))

Autre désignation: LYVE1

Sujet: LYVE-1 has been identified as a major receptor for HA (extracellular matrix glycosaminoglycan hyaluronan) on the lymph vessel wall. The deduced amino acid sequence of LYVE-1 predicts a 322-residue type I integral membrane polypeptide 41% similar to the CD44 HA receptor with a 212-residue extracellular domain containing a single Link module the prototypic HA binding domain of the Link protein superfamily.

Pathways: Glycosaminoglycan Metabolic Process